Zenocutuzumab not checked
Partner Therapeutics, Inc. · MCLA-128
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “full length IgG1 bispecific antibody targeting HER2 and HER3”In the company’s words, NCT02912949 on ClinicalTrials.gov
- Tested for
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Main trialPhase 2
- “This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)”In the company’s words, NCT02912949 on ClinicalTrials.gov
- Other names
- bispecific · MCLA-128
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Dec 2026 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | |
| Phase 2Terminated | 3 Jul 2025 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026